PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (1)
2018
-
A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii372